Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 59

Results For "science"

2023 News Found

Syngene International appoints Gaurav Kushwaha as CTO
People | July 28, 2025

Syngene International appoints Gaurav Kushwaha as CTO

Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited


Granules India CEO K V Sitaram Rao resigns
People | July 27, 2025

Granules India CEO K V Sitaram Rao resigns

Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service


Zydus receives tentative approval from USFDA for Ibrutinib tablets
Drug Approval | July 24, 2025

Zydus receives tentative approval from USFDA for Ibrutinib tablets

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad


Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
News | July 24, 2025

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio


UFlex secures Indian patent for waterborne heat seal coating for food, consumer goods packaging
Packaging | July 23, 2025

UFlex secures Indian patent for waterborne heat seal coating for food, consumer goods packaging

The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard


Lonza reports 19% growth in sales in H1
News | July 23, 2025

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook


Torrent Pharma launches nutrition supplement powder Shelcal Total
News | July 23, 2025

Torrent Pharma launches nutrition supplement powder Shelcal Total

Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Miltenyi Biotec and THSTI partner to launch CAR-T Cell and gene therapy training curriculum
News | July 21, 2025

Miltenyi Biotec and THSTI partner to launch CAR-T Cell and gene therapy training curriculum

This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.